Funding
← Back to your selection

Duquesne Family Office

Activity from announced rounds

Activity in this selectionUnited States · Oct 29, 2026 · Aug 1, 2026

Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.

Recorded funding activity

Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.

Sources
Rounds participated in
3
Confirmed lead rounds
0
1 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$840M
3 disclosed · full round size, not this investor’s share

By stage

Series C+2
Series A1

By primary sector

Biotech1
Hardware1
Healthtech1

By country

United States3

Rounds

3 in this selection
Precision Neuroscience

Develops a brain-computer interface intended to help people with paralysis operate digital devices.

$250MSeries D
Participant
Fab2

Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication.

$500MSeries A
Participant